Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday. WHY IT'S ...

NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their ...

Instead of consistently stepping up the dose to a target dose of 2.4 mg as the ... marked doses on the pens (0.25, 0.5, 1.0 ...

The company also provides insulin pens, growth hormone pens ... compared to the Pharmaceuticals median of $277.8 million. Novo Nordisk A/S’s stock is up 3.6% in 2024, down 4.2% in the previous five ...

Novo Nordisk A/S’s appetite-blocking shot semaglutide ... Not only does it require two different drug ingredients, Novo also ...

An estimated 8.4 million people ... of ordering. Novo said last year it would pull its Levemir insulin from the U.S. market ...